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Despite its apparent benefits, high-dose ibuprofen has been infrequently applied to children with cystic fibrosis. We have noted a decrease
in the use of high-dose ibuprofen at our pediatric cystic fibrosis center during the past decade. In this retrospective study, we examined our
clinical experience with high-dose ibuprofen and other anti-inflammatory drugs in cystic fibrosis patients. The medical records of all patients,
ages 5 to 18 years, followed at the cystic fibrosis center from 1995 to 2002, were reviewed and children were classified into two cohorts:
ibuprofen-treated and untreated groups. Patterns of ibuprofen use and pharmacokinetics in treated patients, and for patients who discontinued
ibuprofen, the reasons for stopping the medication, including adverse effects, were assessed. Pulmonary function decline and hospitalization
rates for each group were compared, examining both intent to treat and patients who continued therapy for at least 4 years. Nearly half of the
patients in our pediatric cystic fibrosis center who were prescribed with high-dose ibuprofen discontinued therapy due to adverse events, not
because of poor adherence or patient choice. Neither use of high-dose ibuprofen nor its cessation resulted in a significant change in the rate of
decline in pulmonary function or influenced hospitalization rates.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Inflammation; Cystic fibrosis; Ibuprofen; Corticosteroids1. Introduction
In cystic fibrosis (CF), defective function of the cystic
fibrosis transmembrane conductance regulator (CFTR) in
airway epithelial cells and submucosal glands results in the
chronic involvement of the respiratory tract, manifested by
airway obstruction and bacterial infections of the lung and
paranasal sinuses that begin early in life [1]. While persistent
pulmonary infection contributes to the morbidity of patients
with CF, the intense host inflammatory response accounts for
the progressive, suppurative pulmonary disease, leading to
bronchiectasis and eventually respiratory failure [2–4].Abbreviations: CF, cystic fibrosis; FVC, forced vital capacity; FEV1,
forced expiratory volume in one second.
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show an intense endobronchial inflammatory process
characterized by high concentrations of pro-inflammatory
cytokines and abundant neutrophils, even in patients with
early, stable, or clinically mild disease [5–7]. For the past
two decades, anti-inflammatory agents have also been shown
to slow pulmonary deterioration, providing further evidence
that inflammation is damaging rather than protective [8–10].
Routine use of such therapies has been shown to affect the
course of the disease, especially in younger patients or those
who have milder disease.
For almost a decade, high-dose ibuprofen has been used
to slow deterioration and destruction of the CF lung. A four-
year, randomized double-blind, placebo-controlled trial
compared the efficacy of regular treatment with ibuprofen
with placebo in CF patients with mild lung disease, and
showed that routine use of the anti-inflammatory drug
resulted in a reduced rate of FEV1 decline and lower
incidence of hospitalization [10]. This effect was most
evident in younger patients (under 13 years) and thoseed by Elsevier B.V. All rights reserved.
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using data derived from the Cystic Fibrosis Foundation
(CFF) Patient Registry, showed similar benefits in slowing
pulmonary function deterioration [11].
Despite their apparent benefits, anti-inflammatory drugs
have been infrequently applied to CF patients, often due to
concerns about dose-limiting toxicities [12]. For instance,
high-dose ibuprofen is used in only a small percentage
(5.6%) of CF children and adolescents as reported to the CFF
Patient Registry [13]. During the past decade, we have
witnessed a decrease in the use of high-dose ibuprofen at the
Washington University Pediatric Cystic Fibrosis Center at St.
Louis Children's Hospital. In this retrospective study, we
reviewed our clinical experience with high-dose ibuprofen
and other anti-inflammatory drugs for CF. We examined the
frequency of adverse effects related to ibuprofen use in these
patients in an effort to better understand the barriers to anti-
inflammatory therapy. Likewise, we assessed the impact of
discontinuing ibuprofen on progression of lung disease in
this pediatric CF population, specifically focusing on the
effect of the anti-inflammatory agent on pulmonary function
decline and hospitalization rate.
2. Methods
2.1. Subjects
We reviewed the medical records of all CF patients ages 5
to 18 years and receiving care at the Washington University
Pediatric Cystic Fibrosis Center from 1995 to 2002 for
whom pulmonary function data spanning at least 4 years
were available. Patients were eligible for enrollment if they
had CF diagnosed according to standard clinical and
laboratory criteria. Children and adolescents prescribed
high-dose ibuprofen during this 7-year period were identi-
fied. The routine use of other anti-inflammatory agents (i.e.,
systemic corticosteroids and inhaled topical corticosteroids),
mucolytics (i.e., dornase alfa), and inhaled antibiotics (i.e.,
nebulized tobramycin) for at least 6 consecutive months
were recorded for all patients studied. Other relevant clinical
features, such as pancreatic status and lower respiratory tract
microbiology, were also noted. In patients who had adverse
events related to therapy, the reasons for discontinuing
ibuprofen therapy were determined from the medical record.
The experimental protocol was reviewed and approved by
the Washington University Human Studies Committee
(IRB).
2.2. Ibuprofen pharmacokinetics and dosing
Using established dosing protocols and treatment guide-
lines [10], supported by the Cystic Fibrosis Foundation,
blood levels and ibuprofen pharmacokinetics were per-
formed by the St Louis Children's Hospital Clinical
Laboratory using established methodologies [14] to establish
optimal dosing before patients began regular treatment.Specifically, daily ibuprofen dose was adjusted to achieve
serum concentrations of 50–100 μg/ml. Of note, most
patients treated with high-dose ibuprofen received generic
preparations.
2.3. Pulmonary function studies
Forced vital capacity (FVC) and forced expiratory
volume in 1 s (FEV1) were measured using the American
Thoracic Society guidelines. The best FEV1 percent
predicted each year, using Morris–Polgar standards, for
each patient was used in the analysis. The rate of FEV1
decline was determined by regression analysis of each
calendar year's best FEV1 (percent predicted) to minimize
the effect of short-term fluctuations in lung function due to
pulmonary exacerbations [P1] [15].
2.4. Hospitalizations
For each subject, the medical record was reviewed to
determine the total number of hospitalizations and treatment
with intravenous antibiotics that occurred during the 7-year
period studied. The primary and secondary diagnoses at the
time of hospitalization were identified, and only hospital
admissions for treatment of pulmonary manifestations
related to CF were used to determine annual hospitalization
rates.
2.5. Laboratory studies
Biochemical abnormalities associated with possible renal
or gastrointestinal complications from high-dose ibuprofen
use were reviewed. For the purposes of this analysis,
abnormal laboratory values were defined by serum creatinine
concentrations greater than 1.2 mg/dL, and blood hemoglo-
bin level less than 10 g/dL, an indirect measure of
gastrointestinal bleeding.
2.6. Statistical analysis
All data are reported as the means±standard error of the
mean (SEM). Group comparisons for antibiotic or anti-
inflammatory drug use were made using χ2 analyses.
Statistical analysis for pulmonary function data and
hospitalization rates were determined using 2-tailed Student
unpaired t-test or ANOVA. For all group comparisons,
significance was determined at the level of 0.05.
3. Results
During the period reviewed (1995–2002), a total of 51 CF
patients (57%) were treated with high-dose ibuprofen at the
center. For comparison, data were extracted from charts of
the remaining 39 children or adolescents (43%) who did not
receive treatment with high-dose ibuprofen during this time
(Table 1). The average ages (8.8±0.6 years and 9.5±
Table 1
Description of CF patients at the Washington University Pediatric Cystic
Fibrosis Center, ages 5–18 years
Ibuprofen-treated
(N=51)
Untreated
(N=39)
Age (years) 8.8±0.6 9.5±0.5
Gender (% males) 24 (47%) 19 (49%)
FEV1 (% predicted) 97.9±2.3 97.2±2.7
Pancreatic insufficiency (%) 98 95
Pseudomonas aeruginosa
colonization (%)
87 87
Serum creatinine level (mg/dl) 0.6±0.2 0.7±0.3
Hemoglobin concentration (g/
dl)
12.9±0.8 13.1±0.9
Ibuprofen dose (mg/kg) 22.0±0.2 – –
Data are expressed as means±standard error of the mean. The Ibuprofen-
treated group represents any patient who was prescribed with high-dose
ibuprofen during the 7-year period. The untreated group did not receive
high-dose ibuprofen at any time during the study.
Table 2
Reasons for CF patients to discontinue high-dose ibuprofen at the
Washington University Pediatric Cystic Fibrosis Center
Reason Number (N=47)
Abdominal pain 7 (15%)
Gastrointestinal bleeding 2 (4%)
Elevated serum transaminase levels 2 (4%)
Hemoptysis 2 (4%)
Hematuria 2 (4%)
Renal failure 1 (2%)
Cancer 1 (2%)
Medical non-adherence 1 (2%)
Unknown 3 (6%)
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2.3% and 97.2±2.7% predicted, respectively; p=0.66) of
the ibuprofen-treated and untreated groups at the start of the
study period were not different. Moreover, patients in the
ibuprofen-treated and untreated groups had similar gender
distribution, pancreatic status, and Pseudomonas aeruginosa
colonization. Because of transfer of care, 4 patients who
began therapy were not included in the analysis since
pulmonary function and laboratory data for those individuals
were unavailable for the entire period of treatment. There
were 2 deaths during the review period, 1 each from the
ibuprofen-treated group and the untreated group. Neither
death was related to a complication of ibuprofen therapy.
Children who received ibuprofen therapy and under 5 years
were also excluded from analyses.
Ibuprofen dosages were determined for each patient using
pharmacokinetic studies using guidelines established by
Konstan and colleagues [10,14]. Target peak plasma
ibuprofen concentration for patients was 50 to 100 μg/ml,
which was achieved in all patients treated. The ibuprofen
dose ranged from 14.5 to 32.0 mg/kg/dose. The mean daily
dose from those patients who ultimately discontinued
ibuprofen was not different for those who continued the
anti-inflammatory therapy throughout (21.9±4.1 and 22.1±
3.5 mg/kg/dose, respectively). During the 7-year of the
study, repeated pharmacokinetic studies were performed to
establish the appropriateness of the ibuprofen dose.
The prescribing patterns for high-dose ibuprofen in the
treatment of CF patients varied greatly between caregivers.
From 1995–1999, the time period when all of the CF
children and adolescents treated were prescribed ibuprofen,
3 center physicians cared for 97% of the patients whose
charts were reviewed for this study. The proportion of
patients treated with high-dose ibuprofen by each center
physician was 80%, 60%, and 10%.
A total of 26 children and adolescents regularly
received ibuprofen throughout the entire study of age,
and those who continued therapy were treated for 73 and85 months during the period reviewed. However, many
patients who began ibuprofen during the review period
discontinued the drug. Twenty-one patients (45%) discon-
tinued ibuprofen from 1 to 46 months (median, 17 months)
after starting the drug because of adverse effects (Table 2).
The reasons for discontinuing ibuprofen were varied. The
primary reason for interrupting ibuprofen therapy was
abdominal pain, which accounted for 7 of those patients
who discontinued use of the drug. Ibuprofen was stopped
in 2 patients due to gastrointestinal hemorrhage, one of
which was severe and required admission to the intensive
care unit for multiple blood transfusions and hemodynamic
stabilization. Neither patient has had overt gastrointestinal
bleeding or evidence of portal hypertension during the
6 years after the medication was stopped. During the
period studied, 4 of the 9 patients (44%) who had
significant gastrointestinal signs and symptoms related to
high-dose ibuprofen were treated with H2-blockers or
proton pump inhibitors, which was similar to the overall
use of these drugs in ibuprofen-treated patients (25/51, or
49%). In rare cases, they were used to improve ibuprofen
tolerance. More often, these drugs were prescribed as
adjunctive therapy to enhance effectiveness of pancreatic
enzyme supplements.
Another patient treated with ibuprofen developed acute
renal failure, which also resolved after the medication was
discontinued. Of note, only 1 patient stopped the medication
due to non-adherence, and 3 patients discontinued the
medication for unknown reasons.
We reviewed serial laboratory studies for biochemical
evidence of organ toxicity, including serum creatinine and
hemoglobin concentrations, an indirect measure of gastro-
intestinal blood loss. No difference was found between
treatment groups in the number of patients who had
abnormal laboratory values at any time during the 7-year
review period (data not shown). Based on these results, high-
dose ibuprofen did not appear to be associated with increased
incidence of renal toxicity. Moreover, the ibuprofen-treated
group did not have a higher incidence of anemia. Never-
theless, as noted above, severe complications were found in
2 patients prescribed ibuprofen that required aggressive
interventions and cessation of therapy.
Table 3
Use of other therapies in CF patients treated with high-dose ibuprofen
SC IC TOBI rhDNase
Ibuprofen-treated (N=26) 5 (19%) 12 (46%) 17 (65%) 22 (85%)
Ibuprofen discontinued
(N=21)
3 (14%) 9 (43%) 14 (67%) 19 (90%)
Untreated (N=39) 12 (31%) 14 (36%) 27 (69%) 29 (74%)
SC: systemic corticosteroids; IC: inhaled corticosteroids; TOBI: tobramycin;
rhDNase: recombinant human deoxyribonuclease (dornase alfa). There was
no difference in the use of other drugs, including anti-inflammatory agents,
between treatment groups.
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ibuprofen on pulmonary outcomes, examining lung function
and hospitalization rates in all CF patients prescribed
ibuprofen and subjects who were consistently treated
throughout the period reviewed. Spirometry was performed
regularly (typically every 3 months) on all CF patients ages
5 years or older. In the intent to treat analyses, we found that
the primary outcome measure, rate of FEV1 decline, was not
different between treatment groups regardless of patient age
(ibuprofen-treated, 2.9±0.5% predicted/yr, N=47; un-
treated, 2.3±0.4% predicted/yr, N=39). (Fig. 1a). A similarFig. 1. a. Average FEV1 values for all pediatric CF patients prescribed high-
dose ibuprofen with untreated patients (intent to treat). b. Average FEV1
values for pediatric CF patients who continued high-dose ibuprofen therapy
and untreated patients. c. Average FEV1 values for pediatric CF patients
13 years or younger who continued high-dose ibuprofen and untreated
patients. Shaded circle: ibuprofen-treated, and open circle: untreated. Data
shown are expressed as means±standard error of the mean. There was no
difference in average FEV1 percent predicted between any of the ibuprofen-
treated and untreated groups.result was found when examining CF patients who
completed therapy (ibuprofen-treated, 2.7±0.9% predicted/
yr, N=26). (Fig. 1b). Since previous studies showed greater
benefit from high-dose ibuprofen in younger CF patients, we
specifically examined FEV1 in children who were under age
13 years at the time of enrollment and completed therapy.
Again, we did not detect a significant difference between the
groups (ibuprofen-treated, 1.9±0.4% predicted/yr, N=39;
untreated, 2.3±0.7% predicted/yr, N=35) (Fig. 1c).
In addition to ibuprofen, we examined concomitant
therapies for the treatment of CF lung disease, including
systemic corticosteroids, inhaled corticosteroids, inhaled
topical tobramycin, dornase alfa. There was no difference
in the use of any of these medications between study
groups (Table 3). No difference in FEV1 deterioration was
found between the groups, even when the 13 patients
treated with alternate-day systemic corticosteroids in the
untreated group were excluded from analysis (data not
shown).
Because other factors can influence the progression of CF
lung disease, we matched patients in all ibuprofen-treated
and untreated cohorts based on age (both groups, 8.7±
0.7 years), gender (both groups, 58% male), pancreatic
insufficiency (both groups, 100%), and pretreatment FEV1
(93.4±4.4%, and 95.2±4.3%, respectively), the annual rates
of decline in FEV1 for 12 matched pairs of treated and
untreated CF patients did not differ (ibuprofen-treated, 2.0±
0.6% predicted/yr; and untreated, 2.5±0.6% predicted/yr).
Similarly, when P. aeruginosa colonization was controlled in
the same cohorts (both groups, 86%) during the study period,
7 matched pairs from untreated and completed therapy
cohorts were compared, and again we did not detect a
significant difference in FEV1 decline between groups
(ibuprofen-treated, 2.5±0.8% predicted/yr; and untreated,
2.1±0.7% predicted/yr).
Finally, we examined the hospitalization rate for CF
patients treated with ibuprofen as compared to untreated
children. Only hospitalizations for respiratory illnesses were
included in the analysis. For the 7-year period reviewed,
19% (0.5±0.1 admissions/yr) of the patients treated with
high-dose ibuprofen were hospitalized as a result of
pulmonary exacerbation, which did not differ from CF
patients who were untreated (21%, or 0.5±0.1 admissions/
yr) (Fig. 2). Several patients required extended or multiple
Fig. 2. Annual hospitalization rates for pediatric CF patients who continued
high-dose ibuprofen with untreated patients. Data are expressed as means±
standard deviation. Shaded column (I): ibuprofen-treated; and open column
(N): non-treated patients. There was no statistical difference in yearly
hospitalization rates between treated and untreated groups.
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significant difference between groups.
4. Discussion
Konstan and colleagues demonstrated that high-dose
ibuprofen slowed deterioration in pulmonary function of CF
patients, an impressive effect was most evident in children
under 13 years [10]. Yet, despite its apparent efficacy, high-
dose ibuprofen has not gained favor at most centers. Less
than 6% of eligible patients in the United States are
prescribed the medication [13]. In this study, we retro-
spectively examined the use of regular, high-dose ibuprofen
in CF children at a single center during a 7-year period. The
majority of pediatric patients between 5 and 18 years were
treated with high-dose ibuprofen, but almost half discon-
tinued therapy within 2 years of starting the drug due to
adverse events related to the drug and not because of non-
adherence. Although two patients had severe complications
temporally related to ibuprofen use (i.e., massive gastro-
intestinal hemorrhage and acute renal failure, both with
complete recovery), we were unable to find a higher
frequency of biochemical abnormalities in the ibuprofen-
treated group. We were unable to find a difference in FEV1
values or its rate of decline in children treated with
ibuprofen compared to those who were never treated or
discontinued the anti-inflammatory drug, even after
accounting for factors that influence progression of CF
lung disease, including age, gender, pancreatic insuffi-
ciency, initial FEV1, and bacterial colonization. In addition,
the annual hospitalization rates were similar for ibuprofen-
treated and untreated groups.Pulmonary inflammation contributes to the morbidity and
mortality in CF, and has been considered a therapeutic target
for this disease. Several anti-inflammatory agents have been
found to preserve pulmonary function in treated patients [8–
10], yet the reported use of systemic anti-inflammatory drugs
in 111 centers across the United States was only 19% [12],
which was considerably lower than our experience at
Washington University Pediatric Cystic Fibrosis Center at
St. Louis Children's Hospital, where 66% of the pediatric
patients 5 years or older were treated with either systemic
corticosteroids or ibuprofen during the period reviewed.
There has been wide variation in the use of high-dose
ibuprofen at cystic fibrosis centers in the United States, and
57% of centers do not have any patients receiving regular
treatment with ibuprofen based on data from the 2003 CFF
Patient Registry [13]. Even within a single center, as
described above, we found considerable physician variability
in prescribing ibuprofen to their CF patients.
Although side effects were noted in early clinical trials,
they did not occur more frequently in the ibuprofen-treated
group compared to the placebo group [10,14]. Since then,
there has only been a single case report of toxicity related to
high-dose ibuprofen [16]. Nevertheless, a survey of
physicians at cystic fibrosis centers across the United States
found that the main hesitation in prescribing high-dose
ibuprofen was concerns about safety [12].
Several of the patients discontinued ibuprofen use due to
abdominal pain, yet it is unclear from the medical records
whether it was directly related to the medication. Two
patients did have severe complications that was temporally
related to ibuprofen, and required cessation of therapy and
aggressive medical interventions. These toxicities appeared
to temper the enthusiasm for initiating ibuprofen therapy at
the center.
We did not find that high-dose ibuprofen affected the
rate of decline in pulmonary function or hospitalization
rates in our pediatric center population. We do not have a
clear explanation why our experience differed from
published reports. It does not appear to be related to
systemic corticosteroid use in the “untreated” patient
group, since there was no difference in the rate of FEV1
decline even when those patients were excluded from
analysis. One possible explanation is that patients
prescribed ibuprofen did not take the medication, which
could not be accurately assessed in this retrospective study.
Poor adherence with the treatment regimen could under-
estimate its clinical effects. Another potential reason for
the difference concerns the ibuprofen preparations used in
the center. In contrast to the original study, which treated
subjects with a single, commercial brand, there was not a
consistent ibuprofen preparation used for pharmacokinetic
studies and subsequent treatment at our center. Generic
preparations may have variable ibuprofen content or
inconsistent biological availability that could contribute
to a lack of effect or our greater incidence of adverse
effects.
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treatments, such as inhaled antibiotics and mucolytic agents
which have gained wider acceptance since the original study,
may obviate the need for ibuprofen. Neither nebulized TOBI
(tobramycin) nor Pulmozyme (dornase alfa) were established
(or available) therapies when the initial studies examining
high-dose ibuprofen were performed. These agents directly
or indirectly reduce bacterial burden (and thus the inflam-
matory stimulus) in the CF lung. Indeed, the annual rates of
FEV1 decline in all groups were lower than that reported in
patients described in the original study [10]. At least,
ibuprofen did not appear to have an additive effect with the
other therapies.
It is difficult to make sweeping conclusions based on
retrospective analyses of clinical data. Nevertheless, high-
dose ibuprofen did not result in a significant decrease in
the rate of decline in pulmonary function or influence
hospitalization rates in our center population. With the
increased, routine use of prophylactic antibiotics, inhaled
mucolytics, and other anti-inflammatory agents, it is likely
that these other drugs are having an impact and ibuprofen
is not exhibiting an additive effect. We did not establish
compliance with the use of ibuprofen, and it is possible
that the inconsistent use of ibuprofen may underestimate
its effect. Nevertheless, we believe that our experience may
provide insights about the obstacles to and limitations of
anti-inflammatory therapies for CF.
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